Implementation and sustainability of surgical randomized trials in gynecologic oncology: Adoption beyond publication

Surgical randomized trials have transformed gynecologic oncology by redefining the extent and route of surgery, nodal assessment, and multimodality care. However, the effect of a surgical trial does not end at publication. Unlike medical therapies, surgical interventions depend on operator expertise, team coordination, pathology support and perioperative infrastructure. Beyond controlled trial settings, these conditions may change, creating technical drift, indication drift, and inequitable adoption. Implementation should therefore be considered a distinct, structured phase of surgical research. The period is particularly vulnerable because landmark trials often evaluate de-escalation or technically complex innovations. Expanding de-escalation beyond trial-tested eligibility can cause undertreatment, whereas diffusion of complex procedures without sufficient expertise or infrastructure can increase morbidity. Disparities in access to specialist surgeons, imaging, pathology, molecular testing, perioperative support, and long-term follow-up amplify these risks. Responsible translation requires trial reports to define the technical, institutional, and patient-selection conditions under which outcomes were achieved. Strategies may include credentialing expectations, operative standards, and risk-appropriate guidelines. Once findings sufficiently resolve equipoise, post-implementation surveillance should determine whether effective procedures are adopted-or ineffective ones abandoned-and whether appropriate use, technical fidelity, safety, equity, and outcomes are maintained as practice spreads. Secondary databases can evaluate utilization, perioperative safety, equity, practice-change attribution, and selected real-world outcomes at scale, but incompletely capture appropriateness, technical fidelity, granular complications, recurrence, and patient-reported quality of life. Surveillance should therefore use a multilevel approach that matches each objective to where information is generated and supplements broad databases with targeted clinical, procedural, and patient-reported data. Treated as an active research phase, surveillance can ensure that surgical innovation reaches the right patients and settings, with outcomes consistent with the supporting evidence.